Upstream Bio Inc UPB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
These beaten-down stocks could bounce back in January, if history is any guide
-
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
-
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
-
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
Trading Information
- Previous Close Price
- $3.42
- Day Range
- $3.29–3.56
- 52-Week Range
- $3.29–33.68
- Bid/Ask
- $3.20 / $3.82
- Shares Outstanding
- 54.77M
- Market Cap
- $184.58M
- Volume/Avg
- 1M / 689,087
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 60.96
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 75
- Website
- https://www.upstreambio.com
Valuation
|
Metric
|
UPB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.72 |
Price/Sales | 60.96 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
UPB
|
|---|---|
Quick Ratio | 26.38 |
Current Ratio | 27.99 |
Interest Coverage | — |
Quick Ratio
UPB
Profitability
|
Metric
|
UPB
|
|---|---|
Return on Assets (Normalized) | −40.35% |
Return on Equity (Normalized) | −41.83% |
Return on Invested Capital (Normalized) | −45.62% |
Return on Assets
UPB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|S$gzCC# | LOCK|<hCZQ | $126B | |||
| Moderna Inc
MRNA
| LOCK|$$>XWkV | LOCK|>< | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>N&NsWQ | LOCK|%sWL | $80B | |||
| argenx SE ADR
ARGX
| LOCK|#&&?@q& | LOCK|mMq | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|B$hy%& | LOCK|?# | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|H&XR<#V | LOCK|nx>Wc | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!^l!%qP% | LOCK|j$wB$ | $26B | |||
| Incyte Corp
INCY
| LOCK|vjJc!<F | LOCK|JT& | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|%#bMq! | LOCK|l^ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|x$#wLsc | LOCK|@T | $14B |
United States